CNSX:BE - Beleave Stock Price, News & Analysis

$0.06
0.00 (0.00 %)
(As of 08/23/2019 07:26 AM ET)
Today's Range
$0.0650
Now: $0.0650
$0.07
50-Day Range
$0.0650
MA: $0.07
$0.08
52-Week Range N/A
Volume136,101 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Beleave Inc., together with its subsidiaries, cultivates, produces, and sells tetrahydrocannabinol and cannabidiol medical cannabis in Canada and Colombia. The company produces cannabis oils and extracts for medical purposes. It also operates a network of medical cannabis clinics under the Medi-Green banner. Beleave Inc. is headquartered in Hamilton, Canada.

Industry, Sector and Symbol

Industry Medicinals & botanicals
Sub-IndustryCannabis
SectorMedical
CUSIPN/A
CIKN/A
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableOptionable

Receive BE News and Ratings via Email

Sign-up to receive the latest news and ratings for BE and its competitors with MarketBeat's FREE daily newsletter.


Beleave (CNSX:BE) Frequently Asked Questions

What is Beleave's stock symbol?

Beleave trades on the CNSX under the ticker symbol "BE."

What price target have analysts set for BE?

1 equities research analysts have issued 12 month price objectives for Beleave's shares. Their predictions range from $0.57 to $0.57. On average, they expect Beleave's stock price to reach $0.57 in the next year. This suggests a possible upside of 776.9% from the stock's current price. View Analyst Price Targets for Beleave.

What is the consensus analysts' recommendation for Beleave?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Beleave in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Beleave.

Has Beleave been receiving favorable news coverage?

Media stories about BE stock have been trending positive on Friday, according to InfoTrie. The research group scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Beleave earned a media sentiment score of 2.5 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the company's share price in the near term. View News Stories for Beleave.

Who are some of Beleave's key competitors?

What other stocks do shareholders of Beleave own?

How do I buy shares of Beleave?

Shares of BE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Beleave's stock price today?

One share of BE stock can currently be purchased for approximately $0.0650.


MarketBeat Community Rating for Beleave (CNSX BE)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  36 (Vote Outperform)
Underperform Votes:  34 (Vote Underperform)
Total Votes:  70
MarketBeat's community ratings are surveys of what our community members think about Beleave and other stocks. Vote "Outperform" if you believe BE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel